Nonbiologic drugs in pediatric rheumatology
Pediatric Rheumatology: A Clinical Viewpoint, Page: 55-75
2016
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
Book Chapter Description
The field of pediatric rheumatology has seen a decisive change in the way patients are being treated in last few decades. The diseases of this subspeciality be it JIA, SLE, vasculitis or JDM are chronic and require long term term treatment with drugs. The discovery of new drugs including BRMs and intelligent use of older drugs have made it possible to achieve remission in many of these conditions and provide patients with a better quality of life. This chapter highlights the pharmacology, intended uses and possible adverse side effects of many of these drugs. The information provided in this chapter should be a precursor for treating children with rheumatological illness.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85018607696&origin=inward; http://dx.doi.org/10.1007/978-981-10-1750-6_7; http://link.springer.com/10.1007/978-981-10-1750-6_7; https://dx.doi.org/10.1007/978-981-10-1750-6_7; https://link.springer.com/chapter/10.1007/978-981-10-1750-6_7
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know